186 related articles for article (PubMed ID: 36047381)
1. Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial.
Hohmann LA; Fox BI; Garza KB; Wang CH; Correia C; Curran GM; Westrick SC
Ann Pharmacother; 2023 Jun; 57(6):677-695. PubMed ID: 36047381
[TBL] [Abstract][Full Text] [Related]
2. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
3. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
4. Pharmacists' perceptions regarding feasibility, acceptability, and usefulness of student-delivered naloxone education services in community pharmacy: A mixed methods study in Alabama.
Hohmann L; Maxson R; McDowell L
J Am Pharm Assoc (2003); 2023; 63(6):1731-1742.e4. PubMed ID: 37619850
[TBL] [Abstract][Full Text] [Related]
5. Increasing use of immunization information systems for routine vaccinations in independent community pharmacies: A randomized controlled trial.
Hastings TJ; Ha D; Fox BI; Qian J; Lakin J; Westrick SC
J Am Pharm Assoc (2003); 2022; 62(4):1270-1279.e2. PubMed ID: 35292212
[TBL] [Abstract][Full Text] [Related]
6. CONSIDER New Mexico: Effects of naloxone training among pharmacists and pharmacy technicians.
Cruz TH; Bachyrycz A; Rodriguez DE; Ma X; Roberts MH; Chambers S; Rafi J; Sanchez A; Bakhireva L
J Am Pharm Assoc (2003); 2022; 62(3):757-765. PubMed ID: 35016857
[TBL] [Abstract][Full Text] [Related]
7. Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder.
Zalmai R; Hill LG; Loera LJ; Mosgrove Q; Brown C
J Am Pharm Assoc (2003); 2023; 63(5):1558-1565.e4. PubMed ID: 37331654
[TBL] [Abstract][Full Text] [Related]
8. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of mandatory alerts on long-acting opioid prescriptions and the use of a community pharmacy naloxone protocol.
Coffman R; Johnson A; Frede S; Pleiman M; Johnson K
J Am Pharm Assoc (2003); 2022; 62(4S):S35-S40.e1. PubMed ID: 34930681
[TBL] [Abstract][Full Text] [Related]
10. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
11. Enhancing pharmacy personnel immunization-related confidence, perceived barriers, and perceived influence: The We Immunize program.
Hastings TJ; Hohmann LA; Huston SA; Ha D; Westrick SC; Garza KB
J Am Pharm Assoc (2003); 2020; 60(2):344-351.e2. PubMed ID: 31735650
[TBL] [Abstract][Full Text] [Related]
12. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
13. Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
Eldridge LA; Meyerson BE; Agley J
J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with how often community pharmacists offer and dispense naloxone.
Carpenter DM; Dhamanaskar AK; Gallegos KL; Shepherd G; Mosley SL; Roberts CA
Res Social Adm Pharm; 2019 Dec; 15(12):1415-1418. PubMed ID: 30007530
[TBL] [Abstract][Full Text] [Related]
15. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
16. Alabama Community Pharmacists' Knowledge and Perceptions Regarding Fentanyl Test Strips: A Cross-Sectional Survey.
Woods S; Blythe E; Valle-Ramos G; Richardson J; Pham K; Diggs K; Harris K; Zhao Y; Hohmann L
J Am Pharm Assoc (2003); 2024 Jun; ():102148. PubMed ID: 38914293
[TBL] [Abstract][Full Text] [Related]
17. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
18. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial.
Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM
Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283
[TBL] [Abstract][Full Text] [Related]
19. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
[TBL] [Abstract][Full Text] [Related]
20. Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.
Pollini RA; Slocum S; Ozga J; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(1):157-166. PubMed ID: 34511372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
